NovaCardia (NCAR) Files $86.25 Million IPO
NovaCardia (Nasdaq: NCAR) filed a registration statement with the SEC for an initial public offering. The proposed maximum aggregate offering price is $86.25 million. The Company intends to apply to list it's common stock on The NASDAQ Global Market under the symbol "NCAR".
The offering is being made through JPMorgan, Credit Suisse, Pacific Growth Equities, LLC and First Albany Capital.
NovaCardia is a clinical-stage pharmaceutical company focused on developing drugs to treat major cardiovascular diseases that are underserved by existing therapies.
The offering is being made through JPMorgan, Credit Suisse, Pacific Growth Equities, LLC and First Albany Capital.
NovaCardia is a clinical-stage pharmaceutical company focused on developing drugs to treat major cardiovascular diseases that are underserved by existing therapies.
You May Also Be Interested In
- UBS Maintains a 'Neutral' on Equity Residential (EQR); Lehman Walks Away With Archstone Stake; IPO Could Be On The Way
- NASDAQ Confirms Facebook (FB) IPO Will Open at 11AM ET
- Canaccord Genuity Morning Coffee on Facebook (Nasdaq: FB): Hitting the Un-Like Button
Create E-mail Alert Related Categories
IPOsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
